Infliximab for hidradenitis suppurativa
T P Sullivan1, E Welsh, F A Kerdel
1Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine/Cedars Medical Center, 1400 NW 12th Ave. 6 South Dermatology, Miami, FL 33136, USA.
The British Journal of Dermatology
|November 25, 2003
Summary
Infliximab significantly reduced disease activity in patients with hidradenitis suppurativa (HS). This treatment showed both patient-reported and physician-observed improvements, indicating its potential for managing this chronic inflammatory condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with limited effective treatments.
- Tumor necrosis factor-alpha (TNF-alpha) plays a key role in inflammatory processes.
- Infliximab, a TNF-alpha inhibitor, has shown efficacy in other inflammatory diseases.
Purpose of the Study:
- To retrospectively evaluate the effectiveness of infliximab in treating hidradenitis suppurativa.
- Assess the impact of infliximab on HS disease activity.
Main Methods:
- Retrospective chart review of HS patients treated with infliximab at the University of Miami.
- Patients retrospectively reported disease activity before and after infliximab therapy.
Main Results:
- Significant decrease in self-reported HS disease activity scores post-infliximab treatment (P = 0.0001).
- Patient-reported outcomes correlated with physician-observed clinical improvement.
Conclusions:
- Infliximab demonstrates promise as a therapeutic agent for hidradenitis suppurativa.
- Initial findings suggest infliximab offers both subjective and objective benefits for HS patients.
- Further controlled studies are needed to confirm infliximab's efficacy and long-term effects on HS.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...